Stocks · News reference
Piper Sandler Maintains Neutral on GRAIL, Raises Price Target to $130
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Grail Exec Expects FDA Decision On Approval For Galleri Cancer Test By Early Q1 2027; Expects Galleri Cancer Test To Be Reimbursed At $500 To $600
GRAIL Exec Expects Broad Label For Galleri Cancer Test Based On Data Co Has Submitted To FDA
RBC Capital Maintains Sector Perform on GRAIL, Raises Price Target to $100
RBC Raises Price Target on GRAIL, Inc.
RBC increased its price target for GRAIL, Inc. to $100 from $84 while maintaining a Sector Perform rating.
GRAIL, Inc. 12-Month Price Target Raised to $134.33
Analysts have increased the 12-month price target for GRAIL, Inc. to $134.33, maintaining a consensus "Buy" rating.